{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T11:29:12Z","timestamp":1745839752965},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,3,1]]},"DOI":"10.2169\/internalmedicine.6314-20","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T22:08:59Z","timestamp":1630361339000},"page":"679-685","source":"Crossref","is-referenced-by-count":2,"title":["Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression"],"prefix":"10.2169","volume":"61","author":[{"given":"Tomoko","family":"Mizuno","sequence":"first","affiliation":[{"name":"Department of Endocrinolgy and Metabolism, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Inoshita","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology Hospital, Japan"},{"name":"Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Tatsushima","sequence":"additional","affiliation":[{"name":"Department of Endocrinolgy and Metabolism, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Takeshita","sequence":"additional","affiliation":[{"name":"Department of Endocrinolgy and Metabolism, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shozo","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Japan"},{"name":"Neurosurgery Center, Moriyama Memorial Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Endocrinolgy and Metabolism, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). 1932. Obes Res 2: 486-508, 1994.","DOI":"10.1002\/j.1550-8528.1994.tb00097.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Graversen D, Vestergaard P, Stochholm K, Gravholt CH, J\u00f8rgensen JO. Mortality in Cushing&apos;s syndrome: a systematic review and meta-analysis. Eur J Intern Med 23: 278-282, 2012.","DOI":"10.1016\/j.ejim.2011.10.013"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Tateno T, Kato M, Tani Y, Oyama K, Yamada S, Hirata Y. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocr J 56: 579-584, 2009.","DOI":"10.1507\/endocrj.K08E-186"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ma P, Wang Y, van der Hoek J, et al. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin Pharmacol Ther 78: 69-80, 2005.","DOI":"10.1016\/j.clpt.2005.04.003"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Wang M, Shen M, He W, et al. The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly. Endocr J 63: 819-834, 2016.","DOI":"10.1507\/endocrj.EJ16-0175"},{"key":"6","unstructured":"6. Osamura RY, Grossman A, Korbonits M, et al. Pituitary adenoma. In: WHO Classification of Tumours of Endocrine Organs. vol. 10 4th ed. Lloyd RV, Osamura RY, Kl\u00f6ppel G, Rosai J, Eds. World Health Organization: International Agency for Research on Cancer, Lyon, 2017: 14-18."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Gomez-Hernandez K, Ezzat S, Asa SL, Mete \u00d6. Clinical implications of accurate subtyping of pituitary adenomas: perspectives from the treating physician. Turk Patoloji Derg 31: 4-17, 2015.","DOI":"10.5146\/tjpath.2015.01311"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kontogeorgos G. Innovations and controversies in the WHO classification of pituitary adenomas. Acta Neuropathol 111: 73-75, 2006.","DOI":"10.1007\/s00401-005-1100-y"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Trouillas J, Roy P, Sturm N, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126: 123-135, 2013.","DOI":"10.1007\/s00401-013-1084-y"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. George DH, Scheithauer BW, Kovacs K, et al. Crooke&apos;s cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol 27: 1330-1336, 2003.","DOI":"10.1097\/00000478-200310000-00005"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yamada S, Inoshita N, Fukuhara N, et al. Therapeutic outcomes in patients undergoing surgery after diagnosis of Cushing&apos;s disease: a single-center study. Endocr J 62: 1115-1125, 2015.","DOI":"10.1507\/endocrj.15-0463"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Reincke M, Sbiera S, Hayakawa A, et al. Mutations in the deubiquitinase gene <i>USP8<\/i> cause Cushing&apos;s disease. Nat Genet 47: 31-38, 2015.","DOI":"10.1038\/ng.3166"},{"key":"13","unstructured":"13. Ma ZY, Song ZJ, Chen JH, et al. Recurrent gain-of-function <i>USP8<\/i> mutations in Cushing&apos;s disease. Cell Res 25: 306-317, 2015."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Chen J, Jian X, Deng S, et al. Identification of recurrent <i>USP48<\/i> and <i>BRAF<\/i> mutations in Cushing&apos;s disease. Nat Commun 9: 3171, 2018.","DOI":"10.1038\/s41467-018-05275-5"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Sperveslage J, Gierke M, Capper D, et al. VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation. Acta Neuropathol 125: 911-912, 2013.","DOI":"10.1007\/s00401-013-1118-5"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sugai T, Nakamura SI, Habano W. Usefulness of proliferative activity, DNA ploidy pattern and p53 products as diagnostic adjuncts in colorectal adenomas and intramucosal carcinomas. Pathol Int 49: 617-625, 1999.","DOI":"10.1046\/j.1440-1827.1999.00914.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Pivonello R, Arnaldi G, Scaroni C, et al. The medical treatment with pasireotide in Cushing&apos;s disease: an Italian multicentre experience based on &quot;real-world evidence&quot; . Endocrine 64: 657-672, 2019.","DOI":"10.1007\/s12020-018-1818-7"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Iacovazzo D, Carlsen E, Lugli F, et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol 174: 241-250, 2016.","DOI":"10.1530\/EJE-15-0832"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Volante M, Brizzi MP, Faggiano A, et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20: 1172-1182, 2007.","DOI":"10.1038\/modpathol.3800954"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kasajima A, Papotti M, Ito W, et al. High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs. Hum Pathol 72: 144-152, 2018.","DOI":"10.1016\/j.humpath.2017.11.008"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Muhammad A, Coopmans EC, Gatto F, et al. Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression. J Clin Endocrinol Metab 104: 915-924, 2019.","DOI":"10.1210\/jc.2018-01524"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Hayashi K, Inoshita N, Kawaguchi K, et al. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing&apos;s disease. Eur J Endocrinol 174: 213-226, 2016.","DOI":"10.1530\/EJE-15-0689"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary 16: 490-498, 2013.","DOI":"10.1007\/s11102-012-0445-1"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Castellnou S, Vasiljevic A, Lapras V, et al. SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors. Endocr Connect 9: 243-253, 2020.","DOI":"10.1530\/EC-20-0035"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/5\/61_6314-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:09:32Z","timestamp":1715231372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/5\/61_6314-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6314-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]},"article-number":"6314-20"}}